Quick Answer
Keros Therapeutics, Inc. reported Operating Income of $67.57 million for fiscal year 2025.
Keros Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $67.57M | +132.0% |
| 2024 | -$210.83M | -24.1% |
| 2023 | -$169.94M | -48.0% |
| 2022 | -$114.79M | -103.6% |
| 2021 | -$56.37M | -20.8% |
| 2020 | -$46.66M | -341.7% |
| 2019 | -$10.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.38M | +73.8% | +61.4% |
| June 30, 2025 | -$39.82M | +21.1% | -126.2% |
| March 31, 2025 | $152.04M | +413.6% | +359.2% |
| September 30, 2024 | -$58.66M | -35.5% | -16.3% |
| June 30, 2024 | -$50.44M | -22.0% | -4.0% |
| March 31, 2024 | -$48.48M | -24.7% | -12.0% |
| September 30, 2023 | -$43.28M | -54.7% | -4.7% |
| June 30, 2023 | -$41.34M | -34.5% | -6.3% |
- Keros Therapeutics, Inc. showed an increase of +132.0% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Keros Therapeutics, Inc.’s operating income has grown by 739.7% (from -$10.56 million to $67.57 million).
- The most recent figure is from Keros Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: